不同类型消化道肿瘤患者化疗前后T淋巴细胞亚群变化及其意义

Changes of lymphocyte subsets and its significance in patients with digestive tract tumor before and after chemotherapy

目的探讨不同类型消化道肿瘤患者在化疗前后T细胞亚群总T细胞(CD3+)、T辅助淋巴细胞(CD4+)、T抑制淋巴细胞(CD8+)、CD4+/CD8+比值的变化情况及临床意义。方法应用流式细胞术分析不同类型消化道肿瘤患者在化疗前后及对照组CD3+、CD4+、CD8+细胞百分率和CD4+/CD8+比值。结果消化道肿瘤患者化疗前CD3+、CD4+、CD4+/CD8+比例均低于对照组,CD8+高于对照组,差异均有统计学意义(P<0.05);结肠癌和胃癌患者化疗后CD3+、CD4+百分比较化疗前均增高,CD8+百分比降低,差异均有统计学意义(P<0.05)。直肠癌患者化疗后CD3+百分比较化疗前增高,CD8+百分比降低,差异有统计学意义(P<0.05),CD4+、CD4+/CD8+比值差异无统计学意义(P>0.05)。结论通过检测消化道肿瘤患者T淋巴细胞亚群化疗前后的变化,对了解机体的免疫动态有着重要的临床意义。

Objective To investigate the T cell subsets （CD3＋） T cells, T lymphocytes （CD4＋）, T lymphocytes （CD8＋） and CD4＋/CD8＋ratio digestive tract tumor before and after chemotherapy changes and clinical significance of patients with digestive tract tumor before and after chemotherapy. Methods Flow cytometry was used to analyze the CD3＋, CD4＋, CD8＋cell percentage and the ratio of CD4＋/CD8＋ in different types of gastrointestinal cancer patients before and after chemotherapy and the healthy （control group）. Results Compared with the control group, the former chemotherapy CD3＋, CD4＋, CD4＋/CD8＋ratio of gastrointestinal cancer patients were lower than that of control group （P〈 0.05）, and CD8＋was higher than the control group （P〈0.05）, the differences were statistically significant. Colon cancer and stom-ach cancer patients after chemotherapy CD3＋, CD4＋percentages were higher than before chemotherapy （P〈0.05）, the percentage of CD8＋was lower （P〈 0.05）, the differences were statistically significant. Patients with rectal cancer after chemotherapy CD3＋percentage was higher before chemotherapy （P〈0.05）, the percentage of CD8＋was lower （P〈0. 05）, the differences were statistically significant; while CD4＋and CD4＋/CD8＋ratio had no statistical significance （P〉0.05）. Conclusion For the digestive tract tumor, detecting the changes of T lymphocyte subsets to understand the im-mune dynamic, in determining the clinical curative effect, and assess the prognosis monitoring, etc., all have very im-portant clinical significance.